PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Webcasts|March 2, 2026
Adaptive Trial Design and Regulatory Shifts in Biopharma Development
Listen
0:00 / 0:00
Webinar Date/Time: Fri, Mar 27, 2026 11:00 AM EDT
This Drug Digest episode examines how evolving regulatory and quality expectations are reshaping biopharmaceutical development and manufacturing. The episode delivers targeted insights on FDA guidance, adaptive trial design, and compliance strategies shaping biopharma decision-making.
Register Free:
Event Overview:
Across recent biopharma regulatory updates, a clear industry narrative centers around evolving quality and regulatory expectations. In this episode of PharmTech Drug Digest, we examine how dynamic regulatory and quality frameworks are shaping biopharmaceutical development and compliance. From updated vaccine schedule guidance influencing demand and safety dialogue to new FDA draft guidances embracing adaptive trial design and modern evidence standards, these shifts elevate quality expectations, streamline regulatory pathways, and impact clinical development strategies across the biopharma industry.
Key Learning Objectives:
- Evolving FDA and global quality standards
- Adaptive and Bayesian trial designs
- Impact of immunization guidance on compliance
- Risk-based quality and evidence strategies
Who Should Attend:
- Quality assurance professionals
- Regulatory affairs leaders
- CMC and technical operations specialists
- Clinical development scientists
Register Free:
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.